{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:54:29Z","timestamp":1790787269315,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-026-03205-0","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T13:46:33Z","timestamp":1778507193000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the lipid accumulation product for MASLD risk stratification in type 2 diabetes: establishing sex-specific thresholds and clinical utility"],"prefix":"10.1186","volume":"25","author":[{"given":"Xiaoxiao","family":"Qu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqun","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanmei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanzi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghua","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-2988","authenticated-orcid":false,"given":"Qipeng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"3205_CR1","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.tem.2024.02.007","volume":"35","author":"L Miao","year":"2024","unstructured":"Miao L, Targher G, Byrne CD, Cao Y-Y, Zheng M-H. Current status and future trends of the global burden of MASLD. Trends Endocrinol Metab. 2024;35:697\u2013707. https:\/\/doi.org\/10.1016\/j.tem.2024.02.007.","journal-title":"Trends Endocrinol Metab"},{"key":"3205_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13098-024-01286-z","volume":"16","author":"AF Godoy-Matos","year":"2024","unstructured":"Godoy-Matos AF, Val\u00e9rio CM, Silva J\u00fanior WS, de Araujo-Neto JM, Bertoluci MC. Correction: 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction\u2013associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes. Diabetol Metab Syndr. 2024;16:54. https:\/\/doi.org\/10.1186\/s13098-024-01286-z.","journal-title":"Diabetol Metab Syndr"},{"key":"3205_CR3","doi-asserted-by":"publisher","first-page":"100638","DOI":"10.1016\/j.ajpc.2024.100638","volume":"17","author":"M Nguyen","year":"2024","unstructured":"Nguyen M, Asgharpour A, Dixon DL, Sanyal AJ, Mehta A. Emerging therapies for MASLD and their impact on plasma lipids. Am J Prev Cardiol. 2024;17:100638. https:\/\/doi.org\/10.1016\/j.ajpc.2024.100638.","journal-title":"Am J Prev Cardiol"},{"key":"3205_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12933-025-02576-0","volume":"24","author":"H Zhang","year":"2025","unstructured":"Zhang H, Tu Z, Liu S, Wang J, Shi J, Li X, et al. Association of different insulin resistance surrogates with all-cause and cardiovascular mortality among the population with cardiometabolic multimorbidity. Cardiovasc Diabetol. 2025;24:33. https:\/\/doi.org\/10.1186\/s12933-025-02576-0.","journal-title":"Cardiovasc Diabetol"},{"key":"3205_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12933-025-02716-6","volume":"24","author":"Z Song","year":"2025","unstructured":"Song Z, Miao X, Liu S, Hu M, Xie X, Sun Y, et al. Associations between cardiometabolic indices and the onset of metabolic dysfunction-associated steatotic liver disease as well as its progression to liver fibrosis: a cohort study. Cardiovasc Diabetol. 2025;24:154. https:\/\/doi.org\/10.1186\/s12933-025-02716-6.","journal-title":"Cardiovasc Diabetol"},{"key":"3205_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12933-024-02334-8","volume":"23","author":"M Duan","year":"2024","unstructured":"Duan M, Zhao X, Li S, Miao G, Bai L, Zhang Q, et al. Metabolic score for insulin resistance (METS-IR) predicts all-cause and cardiovascular mortality in the general population: evidence from NHANES 2001\u20132018. Cardiovasc Diabetol. 2024;23:243. https:\/\/doi.org\/10.1186\/s12933-024-02334-8.","journal-title":"Cardiovasc Diabetol"},{"key":"3205_CR7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12933-025-02758-w","volume":"24","author":"X Gao","year":"2025","unstructured":"Gao X, Chen T, Zhou F, Sun Y, Zhang J, Li X, et al. The association between different insulin resistance surrogates and all-cause mortality and cardiovascular mortality in patients with metabolic dysfunction-associated steatotic liver disease. Cardiovasc Diabetol. 2025;24:200. https:\/\/doi.org\/10.1186\/s12933-025-02758-w.","journal-title":"Cardiovasc Diabetol"},{"key":"3205_CR8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12933-025-02587-x","volume":"24","author":"J Liu","year":"2025","unstructured":"Liu J, Fu Y, Liang P, Song Z, Li Y, Wu H. The association between novel metabolic parameters and all-cause\/cardiovascular mortality in patients with metabolic syndrome is modified by age. Cardiovasc Diabetol. 2025;24:96. https:\/\/doi.org\/10.1186\/s12933-025-02587-x.","journal-title":"Cardiovasc Diabetol"},{"key":"3205_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-026-03112-4","author":"G Yang","year":"2026","unstructured":"Yang G, He W, Qiu X, Shen S, Li P, Feng Y, et al. Triglyceride glucose index-a body shape index (TyG-ABSI) outperforms traditional obesity indices in predicting all-cause and cardiovascular mortality in metabolic-dysfunction associated steatotic liver disease: the mediating role of biological aging. Cardiovasc Diabetol. 2026. https:\/\/doi.org\/10.1186\/s12933-026-03112-4.","journal-title":"Cardiovasc Diabetol"},{"key":"3205_CR10","doi-asserted-by":"publisher","first-page":"1624440","DOI":"10.3389\/fnut.2025.1624440","volume":"12","author":"Y Tang","year":"2025","unstructured":"Tang Y, Gu C. Epidemiological transition of metabolic dysfunction-associated steatotic liver disease-related chronic liver disease and cirrhosis: a comparative study between China and the global population (1990\u20132021). Front Nutr. 2025;12:1624440. https:\/\/doi.org\/10.3389\/fnut.2025.1624440.","journal-title":"Front Nutr"},{"key":"3205_CR11","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/MCG.0000000000002055","volume":"59","author":"R Li","year":"2025","unstructured":"Li R, Li H, Ye X, Qin J. Metabolic Dysfunction-associated Steatotic Liver Disease is Becoming the Leading Driver of the Burden of Cirrhosis in China: Results From the Global Burden of Disease Study 2019. J Clin Gastroenterol. 2025;59:592\u20137. https:\/\/doi.org\/10.1097\/MCG.0000000000002055.","journal-title":"J Clin Gastroenterol"},{"key":"3205_CR12","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1111\/dom.70326","volume":"28","author":"Y Ma","year":"2026","unstructured":"Ma Y, Zhang C, Tian M, Hu J, Wang M, Liu S. Non-invasive diagnosis of metabolic dysfunction-associated steatotic liver disease: Current status, challenges, and future directions. Diabetes Obes Metab. 2026;28:1603\u201313. https:\/\/doi.org\/10.1111\/dom.70326.","journal-title":"Diabetes Obes Metab"},{"key":"3205_CR13","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1111\/apt.70051","volume":"61","author":"Z Liu","year":"2025","unstructured":"Liu Z, Huang J, Dai L, Yuan H, Jiang Y, Suo C, et al. Steatotic liver disease prevalence in China: a population-based study and meta-analysis of 17.4 million individuals. Aliment Pharmacol Ther. 2025;61:1110\u201322. https:\/\/doi.org\/10.1111\/apt.70051.","journal-title":"Aliment Pharmacol Ther"},{"key":"3205_CR14","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jama.2024.1447","volume":"331","author":"H Lin","year":"2024","unstructured":"Lin H, Lee HW, Yip TC-F, Tsochatzis E, Petta S, Bugianesi E, et al. Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease. JAMA. 2024;331:1287\u201397. https:\/\/doi.org\/10.1001\/jama.2024.1447.","journal-title":"JAMA"},{"key":"3205_CR15","doi-asserted-by":"publisher","first-page":"e0846","DOI":"10.1097\/HC9.0000000000000846","volume":"9","author":"D Li","year":"2025","unstructured":"Li D, Zhang X. From mechanisms to management: Early detection and improved treatment of MASLD and its related hepatocellular carcinoma. Hepatol Commun. 2025;9:e0846. https:\/\/doi.org\/10.1097\/HC9.0000000000000846.","journal-title":"Hepatol Commun"},{"key":"3205_CR16","doi-asserted-by":"publisher","first-page":"101182","DOI":"10.1016\/j.aohep.2023.101182","volume":"29","author":"ADC Maldonado-Rojas","year":"2024","unstructured":"Maldonado-Rojas ADC, Zuarth-V\u00e1zquez JM, Uribe M, Barbero-Becerra VJ. Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents. Ann Hepatol. 2024;29:101182. https:\/\/doi.org\/10.1016\/j.aohep.2023.101182.","journal-title":"Ann Hepatol"},{"key":"3205_CR17","doi-asserted-by":"publisher","first-page":"31593","DOI":"10.1038\/s41598-025-17219-3","volume":"15","author":"H Chen","year":"2025","unstructured":"Chen H, Chen Z, Bai X, Li Z, Huang S, Lu D, et al. Metabolic and hepatic biomarkers associated with MASLD in the Chinese population. Sci Rep. 2025;15:31593. https:\/\/doi.org\/10.1038\/s41598-025-17219-3.","journal-title":"Sci Rep"},{"key":"3205_CR18","doi-asserted-by":"publisher","first-page":"e70132","DOI":"10.1111\/eci.70132","volume":"56","author":"A Caturano","year":"2026","unstructured":"Caturano A, Erul E, Nilo R, Nilo D, Russo V, Rinaldi L, et al. Metabolic dysfunction-associated steatotic liver disease, insulin resistance and hepatocellular carcinoma: A deadly triad. Eur J Clin Invest. 2026;56:e70132. https:\/\/doi.org\/10.1111\/eci.70132.","journal-title":"Eur J Clin Invest"},{"key":"3205_CR19","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s00592-015-0715-2","volume":"52","author":"T Du","year":"2015","unstructured":"Du T, Yu X, Zhang J, Sun X. Lipid accumulation product and visceral adiposity index are effective markers for identifying the metabolically obese normal-weight phenotype. Acta Diabetol. 2015;52:855\u201363. https:\/\/doi.org\/10.1007\/s00592-015-0715-2.","journal-title":"Acta Diabetol"},{"key":"3205_CR20","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1471-2261-5-26","volume":"5","author":"HS Kahn","year":"2005","unstructured":"Kahn HS. The lipid accumulation product performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovasc Disord. 2005;5:26. https:\/\/doi.org\/10.1186\/1471-2261-5-26.","journal-title":"BMC Cardiovasc Disord"},{"key":"3205_CR21","doi-asserted-by":"publisher","first-page":"770200","DOI":"10.3389\/fendo.2021.770200","volume":"12","author":"J Yu","year":"2021","unstructured":"Yu J, Yi Q, Hou L, Chen G, Shen Y, Song Y, et al. Transition of lipid accumulation product status and the risk of type 2 diabetes mellitus in middle-aged and older Chinese: a national cohort study. Front Endocrinol (Lausanne). 2021;12:770200. https:\/\/doi.org\/10.3389\/fendo.2021.770200.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3205_CR22","doi-asserted-by":"publisher","first-page":"1163682","DOI":"10.3389\/fendo.2023.1163682","volume":"14","author":"H Wang","year":"2023","unstructured":"Wang H, Zhang Y, Liu Y, Li H, Xu R, Fu H, et al. Comparison between traditional and new obesity measurement index for screening metabolic associated fatty liver disease. Front Endocrinol (Lausanne). 2023;14:1163682. https:\/\/doi.org\/10.3389\/fendo.2023.1163682.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3205_CR23","doi-asserted-by":"publisher","first-page":"889785","DOI":"10.3389\/fendo.2022.889785","volume":"13","author":"Y Li","year":"2022","unstructured":"Li Y, Zheng R, Li S, Cai R, Ni F, Zheng H, et al. Association Between four anthropometric indexes and metabolic syndrome in US adults. Front Endocrinol (Lausanne). 2022;13:889785. https:\/\/doi.org\/10.3389\/fendo.2022.889785.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3205_CR24","doi-asserted-by":"publisher","first-page":"1016581","DOI":"10.3389\/fendo.2022.1016581","volume":"13","author":"Y Duan","year":"2022","unstructured":"Duan Y, Zhang W, Li Z, Niu Y, Chen Y, Liu X, et al. Predictive ability of obesity- and lipid-related indicators for metabolic syndrome in relatively healthy Chinese adults. Front Endocrinol (Lausanne). 2022;13:1016581. https:\/\/doi.org\/10.3389\/fendo.2022.1016581.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3205_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12944-024-02190-1","volume":"23","author":"BS Witarto","year":"2024","unstructured":"Witarto BS, Witarto AP, Visuddho V, Wungu CDK, Maimunah U, Rejeki PS, et al. Gender-specific accuracy of lipid accumulation product index for the screening of metabolic syndrome in general adults: a meta-analysis and comparative analysis with other adiposity indicators. Lipids Health Dis. 2024;23:198. https:\/\/doi.org\/10.1186\/s12944-024-02190-1.","journal-title":"Lipids Health Dis"},{"key":"3205_CR26","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12933-025-02604-z","volume":"24","author":"H-M He","year":"2025","unstructured":"He H-M, Xie Y-Y, Chen Q, Li Y-K, Li X-X, Fu S-J, et al. The synergistic effect of the triglyceride-glucose index and a body shape index on cardiovascular mortality: the construction of a novel cardiovascular risk marker. Cardiovasc Diabetol. 2025;24:69. https:\/\/doi.org\/10.1186\/s12933-025-02604-z.","journal-title":"Cardiovasc Diabetol"},{"key":"3205_CR27","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12933-025-02873-8","volume":"24","author":"J Qiu","year":"2025","unstructured":"Qiu J, Li J, Xu S, Yang J, Zeng H, Zhang Y, et al. Triglyceride glucose-weight-adjusted waist index as a cardiovascular mortality predictor: incremental value beyond the establishment of TyG-related indices. Cardiovasc Diabetol. 2025;24:306. https:\/\/doi.org\/10.1186\/s12933-025-02873-8.","journal-title":"Cardiovasc Diabetol"},{"key":"3205_CR28","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12933-025-02896-1","volume":"24","author":"Y Fan","year":"2025","unstructured":"Fan Y, Ye D, Zhou K, Cai L, Yu L. The novel triglyceride\u2013glucose-weighted adjusted waist index as a supplementary diagnostic tool for heart failure: evidence of improved reclassification beyond traditional TyG-related indices from a cross-sectional study. Cardiovasc Diabetol. 2025;24:329. https:\/\/doi.org\/10.1186\/s12933-025-02896-1.","journal-title":"Cardiovasc Diabetol"},{"key":"3205_CR29","doi-asserted-by":"publisher","first-page":"1163682","DOI":"10.3389\/fendo.2023.1163682","volume":"14","author":"H Wang","year":"2023","unstructured":"Wang H, Zhang Y, Liu Y, Li H, Xu R, Fu H, et al. Comparison between traditional and new obesity measurement index for screening metabolic associated fatty liver disease. Front Endocrinol (Lausanne). 2023;14:1163682. https:\/\/doi.org\/10.3389\/fendo.2023.1163682.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3205_CR30","doi-asserted-by":"publisher","first-page":"e3733","DOI":"10.1002\/dmrr.3733","volume":"40","author":"Y Wang","year":"2024","unstructured":"Wang Y, Wang J, Tao S-Y, Liang Z, Xie R, Liu N-N, et al. Mitochondrial damage-associated molecular patterns: a new insight into metabolic inflammation in type 2 diabetes mellitus. Diabetes Metab Res Rev. 2024;40:e3733. https:\/\/doi.org\/10.1002\/dmrr.3733.","journal-title":"Diabetes Metab Res Rev"},{"key":"3205_CR31","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/ejcn.2017.45","volume":"71","author":"KN Keane","year":"2017","unstructured":"Keane KN, Calton EK, Carlessi R, Hart PH, Newsholme P. The bioenergetics of inflammation: insights into obesity and type 2 diabetes. Eur J Clin Nutr. 2017;71:904\u201312. https:\/\/doi.org\/10.1038\/ejcn.2017.45.","journal-title":"Eur J Clin Nutr"},{"key":"3205_CR32","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1007\/s12072-024-10731-0","volume":"18","author":"M Suoh","year":"2024","unstructured":"Suoh M, Esmaili S, Eslam M, George J. Metabolic (dysfunction)-associated fatty liver disease metrics and contributions to liver research. Hepatol Int. 2024;18:1740\u201355. https:\/\/doi.org\/10.1007\/s12072-024-10731-0.","journal-title":"Hepatol Int"},{"key":"3205_CR33","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12933-024-02354-4","volume":"23","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Wang F, Tang J, Shen L, He J, Chen Y. Association of triglyceride glucose-related parameters with all-cause mortality and cardiovascular disease in NAFLD patients: NHANES 1999\u20132018. Cardiovasc Diabetol. 2024;23:262. https:\/\/doi.org\/10.1186\/s12933-024-02354-4.","journal-title":"Cardiovasc Diabetol"},{"key":"3205_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12933-025-02616-9","volume":"24","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Wu J, Li T, Qu Y, Wang Y. Association of triglyceride-glucose related indices with mortality among individuals with MASLD combined with prediabetes or diabetes. Cardiovasc Diabetol. 2025;24:52. https:\/\/doi.org\/10.1186\/s12933-025-02616-9.","journal-title":"Cardiovasc Diabetol"},{"key":"3205_CR35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12889-024-17645-4","volume":"24","author":"S Dobashi","year":"2024","unstructured":"Dobashi S, Kawaida K, Saito G, Owaki Y, Yoshimoto H. Gender differences in changes in alcohol consumption achieved by free provision of non-alcoholic beverages: a secondary analysis of a randomized controlled trial. BMC Public Health. 2024;24:150. https:\/\/doi.org\/10.1186\/s12889-024-17645-4.","journal-title":"BMC Public Health"},{"key":"3205_CR36","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41575-024-00936-x","volume":"21","author":"BP Lee","year":"2024","unstructured":"Lee BP, Witkiewitz K, Mellinger J, Anania FA, Bataller R, Cotter TG, et al. Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel consensus statement. Nat Rev Gastroenterol Hepatol. 2024;21:626\u201345. https:\/\/doi.org\/10.1038\/s41575-024-00936-x.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3205_CR37","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","volume":"78","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatol Baltim Md. 2023;78:1966\u201386. https:\/\/doi.org\/10.1097\/HEP.0000000000000520.","journal-title":"Hepatol Baltim Md"},{"key":"3205_CR38","doi-asserted-by":"publisher","first-page":"e34934","DOI":"10.1097\/MD.0000000000034934","volume":"103","author":"KC van Son","year":"2024","unstructured":"van Son KC, Te Nijenhuis-Noort LC, Boone SC, Mook-Kanamori DO, Holleboom AG, Roos PR, et al. Prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) in a middle-aged population with overweight and normal liver enzymes, and diagnostic accuracy of noninvasive proxies. Medicine (Baltimore). 2024;103:e34934. https:\/\/doi.org\/10.1097\/MD.0000000000034934.","journal-title":"Medicine (Baltimore)"},{"key":"3205_CR39","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1055\/a-2364-2928","volume":"44","author":"N Thakral","year":"2024","unstructured":"Thakral N, Desalegn H, Diaz LA, Cabrera D, Loomba R, Arrese M, et al. A Precision medicine guided approach to the utilization of biomarkers in MASLD. Semin Liver Dis. 2024;44:273\u201386. https:\/\/doi.org\/10.1055\/a-2364-2928.","journal-title":"Semin Liver Dis"},{"key":"3205_CR40","doi-asserted-by":"publisher","first-page":"3513","DOI":"10.3390\/jcm14103513","volume":"14","author":"H Beyazal Polat","year":"2025","unstructured":"Beyazal Polat H, Beyazal M, Arpa M, K\u0131z\u0131lkaya B, Ayaz T, G\u00fcndo\u011fdu \u00d6L, et al. Exploring the prevalence and risk factors of MASLD in patients with newly diagnosed diabetes mellitus: a comprehensive investigation. J Clin Med. 2025;14:3513. https:\/\/doi.org\/10.3390\/jcm14103513.","journal-title":"J Clin Med"},{"key":"3205_CR41","doi-asserted-by":"publisher","first-page":"1163682","DOI":"10.3389\/fendo.2023.1163682","volume":"14","author":"H Wang","year":"2023","unstructured":"Wang H, Zhang Y, Liu Y, Li H, Xu R, Fu H, et al. Comparison between traditional and new obesity measurement index for screening metabolic associated fatty liver disease. Front Endocrinol (Lausanne). 2023;14:1163682. https:\/\/doi.org\/10.3389\/fendo.2023.1163682.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3205_CR42","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/healthcare8020122","volume":"8","author":"B-K Kim","year":"2020","unstructured":"Kim B-K, Rhee M-Y. Impact of 2018 ESC\/ESH and 2017 ACC\/AHA hypertension guidelines: difference in prevalence of white-coat and masked hypertension. Healthcare, Basel. 2020;8:122. https:\/\/doi.org\/10.3390\/healthcare8020122.","journal-title":"Healthcare, Basel"},{"key":"3205_CR43","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3390\/diagnostics11050787","volume":"11","author":"S Zenovia","year":"2021","unstructured":"Zenovia S, Stanciu C, Sfarti C, Singeap A-M, Cojocariu C, Girleanu I. Vibration-controlled transient elastography and controlled attenuation parameter for the diagnosis of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease. Diagnostics, Basel, Switzerland. 2021;11:787. https:\/\/doi.org\/10.3390\/diagnostics11050787.","journal-title":"Diagnostics, Basel, Switzerland"},{"key":"3205_CR44","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40618-015-0369-5","volume":"39","author":"N Motamed","year":"2016","unstructured":"Motamed N, Razmjou S, Hemmasi G, Maadi M, Zamani F. Lipid accumulation product and metabolic syndrome: a population-based study in northern Iran, Amol. J Endocrinol Invest. 2016;39:375\u201382. https:\/\/doi.org\/10.1007\/s40618-015-0369-5.","journal-title":"J Endocrinol Invest"},{"key":"3205_CR45","doi-asserted-by":"publisher","first-page":"e22283","DOI":"10.1002\/jcla.22283","volume":"32","author":"N Kavaric","year":"2018","unstructured":"Kavaric N, Klisic A, Ninic A. Are visceral adiposity index and lipid accumulation product reliable indices for metabolic disturbances in patients with type 2 diabetes mellitus? J Clin Lab Anal. 2018;32:e22283. https:\/\/doi.org\/10.1002\/jcla.22283.","journal-title":"J Clin Lab Anal"},{"key":"3205_CR46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11892-024-01558-y","volume":"25","author":"KB Kaylan","year":"2024","unstructured":"Kaylan KB, Paul S, NAFLD no more: a review of current guidelines in the diagnosis and evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD). Curr Diab Rep. 2024;25:5. https:\/\/doi.org\/10.1007\/s11892-024-01558-y.","journal-title":"Curr Diab Rep"},{"key":"3205_CR47","doi-asserted-by":"publisher","first-page":"1244405","DOI":"10.3389\/fendo.2023.1244405","volume":"14","author":"G Semmler","year":"2023","unstructured":"Semmler G, Balcar L, Wernly S, V\u00f6lkerer A, Semmler L, Hauptmann L, et al. Insulin resistance and central obesity determine hepatic steatosis and explain cardiovascular risk in steatotic liver disease. Front Endocrinol (Lausanne). 2023;14:1244405. https:\/\/doi.org\/10.3389\/fendo.2023.1244405.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"3205_CR48","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1097\/HEP.0000000000000913","volume":"83","author":"X Qi","year":"2026","unstructured":"Qi X, Li J, Caussy C, Teng G-J, Loomba R. Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease. Hepatol Baltim Md. 2026;83:661\u201378. https:\/\/doi.org\/10.1097\/HEP.0000000000000913.","journal-title":"Hepatol Baltim Md"},{"key":"3205_CR49","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jhep.2009.09.001","volume":"51","author":"S Dasarathy","year":"2009","unstructured":"Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51:1061\u20137. https:\/\/doi.org\/10.1016\/j.jhep.2009.09.001.","journal-title":"J Hepatol"},{"key":"3205_CR50","doi-asserted-by":"publisher","unstructured":"American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care. 2022;45:S17\u201338. https:\/\/doi.org\/10.2337\/dc22-S002.","DOI":"10.2337\/dc22-S002"},{"key":"3205_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i11","volume":"36","author":"MB Kursa","year":"2010","unstructured":"Kursa MB, Rudnicki WR. Feature selection with the Boruta package. J Stat Softw. 2010;36:1\u201313.","journal-title":"J Stat Softw"},{"key":"3205_CR52","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1210\/jc.2010-0288","volume":"95","author":"F Guerrero-Romero","year":"2010","unstructured":"Guerrero-Romero F, Simental-Mend\u00eda LE, Gonz\u00e1lez-Ortiz M, Mart\u00ednez-Abundis E, Ramos-Zavala MG, Hern\u00e1ndez-Gonz\u00e1lez SO, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95:3347\u201351. https:\/\/doi.org\/10.1210\/jc.2010-0288.","journal-title":"J Clin Endocrinol Metab"},{"key":"3205_CR53","doi-asserted-by":"publisher","first-page":"143","DOI":"10.3390\/life11020143","volume":"11","author":"Y Sumida","year":"2021","unstructured":"Sumida Y, Yoneda M, Tokushige K, Kawanaka M, Fujii H, Yoneda M, et al. FIB-4 First in the diagnostic algorithm of metabolic-dysfunction-associated fatty liver disease in the era of the global metabodemic. Life (Basel). 2021;11:143. https:\/\/doi.org\/10.3390\/life11020143","journal-title":"Life (Basel)"},{"key":"3205_CR54","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.2147\/DMSO.S518649","volume":"18","author":"W Liu","year":"2025","unstructured":"Liu W, Xu L, Yu Y, Qiao L, Zhang L, Chu X, et al. Correlation Between Lipid Accumulation product and metabolic dysfunction-associated steatotic liver disease in Chinese adults with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2025;18:2007\u201317. https:\/\/doi.org\/10.2147\/DMSO.S518649.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"3205_CR55","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3390\/medsci13030160","volume":"13","author":"JJ Guarro Miguel","year":"2025","unstructured":"Guarro Miguel JJ, T\u00e1rraga L\u00f3pez PJ, Marzoa Jansana MD, L\u00f3pez-Gonz\u00e1lez \u00c1A, Riutord Sbert P, Busquets-Cort\u00e9s C, et al. Diagnostic accuracy of anthropometric and metabolic indicators for predicting MASLD: evidence from a large cohort of spanish workers Using FLI and LAP. Med Sci (Basel). 2025;13:160. https:\/\/doi.org\/10.3390\/medsci13030160","journal-title":"Med Sci (Basel)"},{"key":"3205_CR56","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jhep.2024.03.023","volume":"81","author":"L Castera","year":"2024","unstructured":"Castera L, Garteiser P, Laouenan C, Vidal-Tr\u00e9can T, Vallet-Pichard A, Manchon P, et al. Prospective head-to-head comparison of non-invasive scores for diagnosis of fibrotic MASH in patients with type 2 diabetes. J Hepatol. 2024;81:195\u2013206. https:\/\/doi.org\/10.1016\/j.jhep.2024.03.023.","journal-title":"J Hepatol"},{"key":"3205_CR57","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1186\/s12967-023-04770-8","volume":"21","author":"N Salvoza","year":"2023","unstructured":"Salvoza N, Giraudi P, Gazzin S, Bonazza D, Palmisano S, de Manzini N, et al. The potential role of omentin-1 in obesity-related metabolic dysfunction-associated steatotic liver disease: evidence from translational studies. J Transl Med. 2023;21:906. https:\/\/doi.org\/10.1186\/s12967-023-04770-8.","journal-title":"J Transl Med"},{"key":"3205_CR58","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3390\/nu16091381","volume":"16","author":"B Zy\u015bk","year":"2024","unstructured":"Zy\u015bk B, Ostrowska L, Smarkusz-Zarzecka J, Orywal K, Mroczko B, Cwalina U. Evaluation of the diagnostic utility of selected serum adipokines and cytokines in subjects with MASLD-a pilot study. Nutrients. 2024;16:1381. https:\/\/doi.org\/10.3390\/nu16091381.","journal-title":"Nutrients"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-026-03205-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03205-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-026-03205-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T02:00:44Z","timestamp":1783303244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-026-03205-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3205"],"URL":"https:\/\/doi.org\/10.1186\/s12933-026-03205-0","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"26 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the Second Affiliated Hospital and Yuying Children\u2019s Hospital of Wenzhou Medical University (No. 2025-K-270-01). Given the retrospective nature of the study and the use of de-identified clinical data, the requirement for written informed consent was waived by the Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"193"}}